

REMARKS

Upon entry of the above preliminary amendment claims 1-26 and 30-37 will be pending in the present application. Applicants have added an Abstract of the Disclosure to conform to U.S. Patent practice. Applicants have amended the specification to correct a subject heading. Applicants have canceled claim 27-29 without prejudice to the subject matter therein. Applicants have amended the claims to conform to U.S. Patent practice and not for purposes of patentability. Claims 1-11 and 16-26 are independent to give 22 independent claims. Applicants have not raised any issue of new matter nor narrowed the claims in any manner.

Conclusion

Applicants respectfully submit that the present application is in condition for allowance.

If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (302) 934-4395, in Millsboro, Delaware.

If necessary, the Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 02-2334 for any

Attorney Docket No. I 2002.032 US

additional fees required under 37 C.F.R. §1.16 or under 37 C.F.R.
§1.17; particularly extension of time fees.

Respectfully submitted

Mark W. Milstead

by W. [Signature] Reg. No. 442 95

Mark W. Milstead
Attorney for Applicants
Registration No. 45,825

Intervet Inc
Akzo Nobel Pharma Patent Dept.
P.O. Box 318
29160 Intervet Lane
Millsboro, DE 19966
Tel: (302) 933-4034
Fax: (302) 934-4305

MWM

Enclosure: **Abstract of the Disclosure**

US EXPRESS MAIL NO.: EV 389657791 US